Alexander Egeberg1, Lone Skov2, Aditya A Joshi3, Lotus Mallbris4, Gunnar H Gislason5, Jashin J Wu6, Justin Rodante3, Joseph B Lerman3, Mark A Ahlman3, Joel M Gelfand7, Nehal N Mehta8. 1. Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Electronic address: alexander.egeberg@gmail.com. 2. Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 3. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 4. Unit of Dermatology and Venerology, Karolinska Institutet, Stockholm, Sweden. 5. Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Danish Heart Foundation, Copenhagen, Denmark; National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. 6. Kaiser Permanente Los Angeles Medical Center, Los Angeles, California. 7. Department of Dermatology, Department of Biostatistics and Epidemiology, and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania. 8. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: nehal.mehta@nih.gov.
Abstract
BACKGROUND: Psoriasis is associated with risk of cardiovascular (CV) disease (CVD) and a major adverse CV event (MACE). Whether psoriasis duration affects risk of vascular inflammation and MACEs has not been well characterized. OBJECTIVES: We utilized two resources to understand the effect of psoriasis duration on vascular disease and CV events: (1) a human imaging study and (2) a population-based study of CVD events. METHODS: First, patients with psoriasis (N = 190) underwent fludeoxyglucose F 18 positron emission tomography/computed tomography (duration effect reported as a β-coefficient). Second, MACE risk was examined by using nationwide registries (adjusted hazard ratios in patients with psoriasis (n = 87,161) versus the general population (n = 4,234,793). RESULTS: In the human imaging study, patients were young, of low CV risk by traditional risk scores, and had a high prevalence of cardiometabolic diseases. Vascular inflammation by fludeoxyglucose F 18 positron emission tomography/computed tomography was significantly associated with disease duration (β = 0.171, P = .002). In the population-based study, psoriasis duration had strong relationship with MACE risk (1.0% per additional year of psoriasis duration [hazard ratio, 1.010; 95% confidence interval, 1.007-1.013]). LIMITATIONS: These studies utilized observational data. CONCLUSION: We found detrimental effects of psoriasis duration on vascular inflammation and MACE, suggesting that cumulative duration of exposure to low-grade chronic inflammation may accelerate vascular disease development and MACEs. Providers should consider inquiring about duration of disease to counsel for heightened CVD risk in psoriasis.
BACKGROUND:Psoriasis is associated with risk of cardiovascular (CV) disease (CVD) and a major adverse CV event (MACE). Whether psoriasis duration affects risk of vascular inflammation and MACEs has not been well characterized. OBJECTIVES: We utilized two resources to understand the effect of psoriasis duration on vascular disease and CV events: (1) a human imaging study and (2) a population-based study of CVD events. METHODS: First, patients with psoriasis (N = 190) underwent fludeoxyglucose F 18 positron emission tomography/computed tomography (duration effect reported as a β-coefficient). Second, MACE risk was examined by using nationwide registries (adjusted hazard ratios in patients with psoriasis (n = 87,161) versus the general population (n = 4,234,793). RESULTS: In the human imaging study, patients were young, of low CV risk by traditional risk scores, and had a high prevalence of cardiometabolic diseases. Vascular inflammation by fludeoxyglucose F 18 positron emission tomography/computed tomography was significantly associated with disease duration (β = 0.171, P = .002). In the population-based study, psoriasis duration had strong relationship with MACE risk (1.0% per additional year of psoriasis duration [hazard ratio, 1.010; 95% confidence interval, 1.007-1.013]). LIMITATIONS: These studies utilized observational data. CONCLUSION: We found detrimental effects of psoriasis duration on vascular inflammation and MACE, suggesting that cumulative duration of exposure to low-grade chronic inflammation may accelerate vascular disease development and MACEs. Providers should consider inquiring about duration of disease to counsel for heightened CVD risk in psoriasis.
Authors: Alexander Egeberg; Jacob P Thyssen; Peter Jensen; Gunnar H Gislason; Lone Skov Journal: Acta Derm Venereol Date: 2017-07-06 Impact factor: 4.437
Authors: Nehal N Mehta; Rahat S Azfar; Daniel B Shin; Andrea L Neimann; Andrea B Troxel; Joel M Gelfand Journal: Eur Heart J Date: 2009-12-27 Impact factor: 29.983
Authors: Zahi A Fayad; Venkatesh Mani; Mark Woodward; David Kallend; Markus Abt; Tracy Burgess; Valentin Fuster; Christie M Ballantyne; Evan A Stein; Jean-Claude Tardif; James H F Rudd; Michael E Farkouh; Ahmed Tawakol Journal: Lancet Date: 2011-09-09 Impact factor: 79.321
Authors: Michael S Garshick; Tessa J Barrett; Todd Wechter; Sarah Azarchi; Jose U Scher; Andrea Neimann; Stuart Katz; Judilyn Fuentes-Duculan; Maria V Cannizzaro; Sanja Jelic; Edward A Fisher; James G Krueger; Jeffrey S Berger Journal: Arterioscler Thromb Vasc Biol Date: 2019-04 Impact factor: 8.311
Authors: Li-Hao Huang; Bernd H Zinselmeyer; Chih-Hao Chang; Brian T Saunders; Andrew Elvington; Osamu Baba; Thomas J Broekelmann; Lina Qi; Joseph S Rueve; Melody A Swartz; Brian S Kim; Robert P Mecham; Helge Wiig; Michael J Thomas; Mary G Sorci-Thomas; Gwendalyn J Randolph Journal: Cell Metab Date: 2018-11-08 Impact factor: 27.287
Authors: Georg Schett; Proton Rahman; Christopher Ritchlin; Iain B McInnes; Dirk Elewaut; Jose U Scher Journal: Nat Rev Rheumatol Date: 2022-05-05 Impact factor: 20.543
Authors: Brittany Weber; David W Biery; Avinainder Singh; Sanjay Divakaran; Adam N Berman; Wanda Y Wu; Jenifer M Brown; Jon Hainer; Khurram Nasir; Katherine Liao; Deepak L Bhatt; Marcelo F Di Carli; Ron Blankstein Journal: Eur J Prev Cardiol Date: 2022-03-11 Impact factor: 7.804